Vitale Antonio, Rigante Donato, Lopalco Giuseppe, Brizi Maria Giuseppina, Caso Francesco, Franceschini Rossella, Denaro Rosario, Galeazzi Mauro, Punzi Leonardo, Iannone Florenzo, Lapadula Giovanni, Simpatico Antonella, Marrani Edoardo, Costa Luisa, Cimaz Rolando, Cantarini Luca
Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy.
Clin Rheumatol. 2014 Aug;33(8):1165-7. doi: 10.1007/s10067-014-2555-9.
Serum amyloid-A (SAA) is an acute phase protein, synthesized by the liver and previously investigated as a marker of disease activity in many rheumatologic disorders. Its significance in Behçet’s disease (BD), a chronic inflammatory disorder at the crossroad between autoimmune and autoinflammatory syndromes, is still unraveled. Our aim was to assess the role of SAA levels as a potential marker of disease activity in patients with BD. According to our findings, the occurrence of oral aphthosis, neurological impairment, and ocular disease is significantly associated with SAA serum levels higher than 30, 50, and 150 mg/L, respectively. We also suggest that increased SAA levels might identify a thrombotic risk in BD with previous or concurrent vascular involvement.
血清淀粉样蛋白A（SAA）是一种急性期蛋白，由肝脏合成，此前在许多风湿性疾病中作为疾病活动的标志物进行过研究。它在白塞病（BD）中的意义仍未明确，白塞病是一种处于自身免疫和自身炎症综合征交叉点的慢性炎症性疾病。我们的目的是评估SAA水平作为BD患者疾病活动潜在标志物的作用。根据我们的研究结果，口腔阿弗他溃疡、神经功能损害和眼部疾病的发生分别与血清SAA水平高于30、50和150mg/L显著相关。我们还认为，SAA水平升高可能提示既往或并发血管受累的BD患者存在血栓形成风险。
